INS and type 2 diabetes mellitus: From 1 January 2010 to 21 December 2023, 176,409 individuals with type 2 diabetes receiving SGLT2i plus insulin, 207,034 receiving GLP1-ra plus insulin and 1,922,312 individuals receiving insulin but no SGLT1i/GLP1-ra were identified.